ACT Signature Webinars

Impurities: The Good, the Bad, and the Ugly 

02-08-2016 01:37 PM

Speaker: Joel Bercu, Associate Director of Environmental and Occupational Toxicology at Gilead Sciences

In collaboration with: British Toxicology Society, and the Society of Toxicologic Pathology

The purpose of drug development is to maximize the Good, which is developing drugs that improve patient’s lives. In the process drug sponsors minimize the Bad, which are impurities since they are do not provide benefit to patients. And finally the Ugly, or potentially toxic impurities, are either avoided or reduced to toxicologically acceptable levels. The purpose of this webinar is to discuss the current ICH guidelines on impurities and the toxicologist’s role in this process to ensure the Good without the Bad or Ugly.

View Webinar Recording

Webinar materials are property of the speaker and the American College of Toxicology and are intended for use by the host society and cohost societies' members for educational purposes only. Any distribution or copy of the materials is prohibited. By downloading from the link provided you agree to the terms expressed above.

0 Favorited
1 Files
pdf file
ACTwebinarimpurities18Jan2016.pdf   1.37 MB   1 version
Uploaded - 08-27-2020

Related Entries and Links

No Related Resource entered.